COMMUNIQUÉS West-GlobeNewswire

VALNEVA to Present at Jefferies and Stifel 2017 Healthcare Conferences
06/11/2017
Valneva to Present at Jefferies and Stifel 2017 Healthcare Conferences Lyon (France), November 06, 2017 - Valneva SE ("Valneva" or "the Company"), a leading commercial stage biotech company focused on developing [...]
Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study
05/11/2017
Galapagos presents data from DARWIN 3, other filgotinib studies and Galapagos' GLPG1972 at American College of Rheumatology Meeting 2017 Mechelen, Belgium; 5 November 2017; 3 PM CET - Galapagos NV (Euronext & NASDAQ [...]
XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
03/11/2017
Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary Thrombosis AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the [...]
Shire plc : Director/PDMR Shareholding
03/11/2017
Director/PDMR Shareholding November 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]
Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
03/11/2017
Reference is made to Targovax ASA's (the "Company") stock exchange notice of 27 October 2017 relating to the board of director's resolutions to increase the share capital in connection with exercise of employee options [...]
NICOX : Suite à l'approbation de VYZULTA, état des activités, des programmes de développement de son portefeuille de produits et point financier
03/11/2017
Communiqué de presse Nicox : suite à l'approbation de VYZULTA TM , état des activités, des programmes de développement de son portefeuille de produits et point financier VYZULTA TM (solution ophtalmique de [...]
Nicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives
03/11/2017
Press Release Nicox Highlights VYZULTA TM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives ................................... VYZULTA TM (latanoprostene bunod ophthalmic solution [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
03/11/2017
REGULATED INFORMATION GHENT, Belgium, 3 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
03/11/2017
pdf version of the press release This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
03/11/2017
REGULATED INFORMATION GHENT, Belgium, 3 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
BAUSCH + LOMB ET NICOX ANNONCENT L'APPROBATION DE LA FDA POUR VYZULTA(TM) (SOLUTION OPHTALMIQUE DE LATANOPROSTÈNE BUNOD), 0,024%
02/11/2017
Contacts: Valeant Relations Investisseurs : Arthur Shannon arthur.shannon@valeant.com +1-514-856-3855 +1-877-281-6642 (toll free) Media: Lainie Keller lainie.keller@valeant.com +1-908-927-0617 Kristy Marks kristy.marks@ [...]
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
02/11/2017
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the Generation Program, which [...]
Medtronic Releases Fiscal Year 2017 Integrated Performance Report
02/11/2017
Report Highlights Company's Global Financial, Social, and Environmental Impact DUBLIN - November 2, 2017 - Medtronic plc (NYSE:MDT) announces the release of its fiscal year 2017 Integrated Performance Report. The report [...]
NICOX : Nombre de droits de vote au 31 octobre 2017
02/11/2017
Nicox SA Société anonyme au capital de 29 169 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 2 novembre 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]
NICOX : Number of voting rights as of October 31, 2017
02/11/2017
Nicox SA Société anonyme with a registered capital of € 29,169,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On November 2, 2017, MONTHLY PUBLICATION OF THE [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
02/11/2017
Information relative au nombre total de droits de vote et d'actions composant le capital social 2 novembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de [...]
Composition of Terveystalo Plc Shareholders' Nomination Board
02/11/2017
Composition of Terveystalo Plc Shareholders' Nomination Board Terveystalo Plc Stock exchange release, 2 November 2017 at 6:20 p.m. Terveystalo's Nomination Board comprises the representatives of the five largest [...]
EastPharma Ltd Sales Update Announcement for the period 30 September 2017
02/11/2017
EASTPHARMA LTD. London, 2 November 2017 - EastPharma (EAST LI) announces that it is releasing its 9M 2017 sales performance and a review of its main subsidiary DEVA Holding's unaudited financial statements for the [...]
Virbac : Déclaration d'actions et de droits de vote au 31 Octobre 2017
02/11/2017
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Pages